{"id":"linagliptin-metformin-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. The combination provides complementary mechanisms to reduce hyperglycemia in type 2 diabetes mellitus.","oneSentence":"Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:16.314Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04670666","phase":"PHASE3","title":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-11-18","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT07213895","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-21","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":14},{"nctId":"NCT07044765","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT07034781","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT01734785","phase":"PHASE3","title":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-02-08","conditions":"Diabetes Mellitus, Type 2","enrollment":607},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04564872","phase":"PHASE3","title":"HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2020-11-13","conditions":"Diabetes Mellitus, Type 2","enrollment":465},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT03259490","phase":"PHASE1","title":"This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-31","conditions":"Healthy","enrollment":30},{"nctId":"NCT02821910","phase":"PHASE1","title":"Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-07-20","conditions":"Healthy","enrollment":50},{"nctId":"NCT03629054","phase":"PHASE1","title":"This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-08-27","conditions":"Healthy","enrollment":30},{"nctId":"NCT04088461","phase":"PHASE4","title":"Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2016-09","conditions":"Prediabetic State, Impaired Glucose Tolerance, Insulin Resistance","enrollment":31},{"nctId":"NCT02061969","phase":"PHASE4","title":"ADA Linagliptin in Long Term Care","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-04-25","conditions":"Diabetes","enrollment":140},{"nctId":"NCT01422876","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1405},{"nctId":"NCT02173639","phase":"PHASE1","title":"Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT00309608","phase":"PHASE2","title":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT01512979","phase":"PHASE4","title":"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 2","enrollment":316},{"nctId":"NCT02097342","phase":"PHASE4","title":"Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Insulin Sensitivity/Resistance","enrollment":30},{"nctId":"NCT00602472","phase":"PHASE3","title":"BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1058},{"nctId":"NCT00996658","phase":"PHASE3","title":"Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":278},{"nctId":"NCT00328172","phase":"PHASE2","title":"Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00622284","phase":"PHASE3","title":"Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1560},{"nctId":"NCT01084005","phase":"PHASE3","title":"Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":241},{"nctId":"NCT00601250","phase":"PHASE3","title":"Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Diabetes Mellitus, Type 2","enrollment":701},{"nctId":"NCT01540487","phase":"PHASE1","title":"Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combined treatment"],"phase":"marketed","status":"active","brandName":"Linagliptin / Metformin Oral Tablet","genericName":"Linagliptin / Metformin Oral Tablet","companyName":"Universidad de Guanajuato","companyId":"universidad-de-guanajuato","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}